These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38570270)

  • 1. Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Tembo G; Mayuni M; Kamng'ona R; Chimgoneko L; Chiwala G; Sichone S; Galafa B; Thole F; Mkandawire C; Chirwa AE; Nsomba E; Nkhoma V; Ngoliwa C; Toto N; Makhaza L; Muyaya A; Kudowa E; Henrion MYR; Dula D; Morton B; Chikaonda T; Gordon SB; Jambo KC
    Vaccine; 2024 Apr; 42(12):2975-2982. PubMed ID: 38570270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
    Wolf AS; Mitsi E; Jones S; Jochems SP; Roalfe L; Thindwa D; Meiring JE; Msefula J; Bonomali F; Makhaza Jere T; Mbewe M; Collins AM; Gordon SB; Gordon MA; Ferreira DM; French N; Goldblatt D; Heyderman RS; Swarthout TD
    Vaccine; 2022 Nov; 40(50):7201-7210. PubMed ID: 36210249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study of controlled human infection with Streptococcus pneumoniae in Malawi.
    Morton B; Burr S; Chikaonda T; Nsomba E; Manda-Taylor L; Henrion MYR; Banda NP; Rylance J; Ferreira DM; Jambo K; Gordon SB;
    EBioMedicine; 2021 Oct; 72():103579. PubMed ID: 34571365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage of Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a randomised controlled trial and controlled human infection study.
    Dula D; Morton B; Chikaonda T; Chirwa AE; Nsomba E; Nkhoma V; Ngoliwa C; Sichone S; Galafa B; Tembo G; Chaponda M; Toto N; Kamng'ona R; Makhaza L; Muyaya A; Thole F; Kudowa E; Howard A; Kenny-Nyazika T; Ndaferankhande J; Mkandawire C; Chiwala G; Chimgoneko L; Banda NPK; Rylance J; Ferreira D; Jambo K; Henrion MYR; Gordon SB;
    Lancet Microbe; 2023 Sep; 4(9):e683-e691. PubMed ID: 37659418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
    Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).
    Liatsikos K; Hyder-Wright A; Pojar S; Chen T; Wang D; Davies K; Myerscough C; Reine J; Robinson RE; Urban B; Mitsi E; Solorzano C; Gordon SB; Quinn A; Pan K; Anderson AS; Theilacker C; Begier E; Gessner BD; Collins A; Ferreira DM;
    BMJ Open; 2022 Jul; 12(7):e062109. PubMed ID: 35798520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High multiple carriage and emergence of Streptococcus pneumoniae vaccine serotype variants in Malawian children.
    Kamng'ona AW; Hinds J; Bar-Zeev N; Gould KA; Chaguza C; Msefula C; Cornick JE; Kulohoma BW; Gray K; Bentley SD; French N; Heyderman RS; Everett DB
    BMC Infect Dis; 2015 Jun; 15():234. PubMed ID: 26088623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol.
    Morton B; Jambo K; Chikaonda T; Rylance J; Henrion MYR; Banda NP; Nsomba E; Gondwe J; Ferreira D; Gordon SB;
    Wellcome Open Res; 2021; 6():240. PubMed ID: 36263101
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
    Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
    Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage.
    Mitsi E; Roche AM; Reiné J; Zangari T; Owugha JT; Pennington SH; Gritzfeld JF; Wright AD; Collins AM; van Selm S; de Jonge MI; Gordon SB; Weiser JN; Ferreira DM
    Mucosal Immunol; 2017 Mar; 10(2):385-394. PubMed ID: 27579859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
    PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
    Lewnard JA; Givon-Lavi N; Dagan R
    Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
    Mitsi E; McLenaghan D; Wolf AS; Jones S; Collins AM; Hyder-Wright AD; Goldblatt D; Heyderman RS; Gordon SB; Ferreira DM
    J Infect Dis; 2022 May; 225(9):1626-1631. PubMed ID: 34159375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media.
    Bogaert D; Veenhoven RH; Ramdin R; Luijendijk IH; Rijkers GT; Sanders EA; de Groot R; Hermans PW
    Vaccine; 2005 Apr; 23(20):2607-13. PubMed ID: 15780443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.